https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-21 / Int. J. Urol. 2017 05;24(5):342-351
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-21 / Int. J. Urol. 2017 05;24(5):342-3512017-03-21 00:00:002017-03-21 00:00:00Current status of clinical trials assessing oncolytic virus therapy for urological cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-05 / Expert Opin Biol Ther 2017 04;17(4):457-474
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-05 / Expert Opin Biol Ther 2017 04;17(4):457-4742017-03-05 00:00:002019-02-15 08:47:44Immune and viral therapies for malignant primary brain tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-03-02 / Crit. Rev. Oncol. Hematol. 2017 May;113:292-303
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-03-02 / Crit. Rev. Oncol. Hematol. 2017 May;113:292-3032017-03-02 00:00:002019-02-15 08:51:58A comprehensive review of immunotherapies in prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-02-27 / Eur. J. Pharmacol. 2017 May;802:85-92
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-02-27 / Eur. J. Pharmacol. 2017 May;802:85-922017-02-27 00:00:002019-02-15 09:13:32Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-12-01 / Urol Oncol 2016 12;34(12):538-547
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-12-01 / Urol Oncol 2016 12;34(12):538-5472016-12-01 00:00:002016-12-01 00:00:00Emerging role of immunotherapy in urothelial carcinoma-Advanced disease
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-10-10 / Stem Cell Res Ther 2016 10;7(1):149
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-10-10 / Stem Cell Res Ther 2016 10;7(1):1492016-10-10 00:00:002019-02-15 09:00:20Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-07-25 / J Urol 2017 01;197(1):14-22
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-07-25 / J Urol 2017 01;197(1):14-222016-07-25 00:00:002016-07-25 00:00:00Immunotherapy for the Treatment of Urothelial Carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-03 / BJU Int. 2016 10;118(4):506-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-03 / BJU Int. 2016 10;118(4):506-142016-06-03 00:00:002019-02-15 08:52:00Recent advances in immuno-oncology and its application to urological cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-06-01 / Expert Opin Emerg Drugs 2016 Jun;21(2):133-45
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-06-01 / Expert Opin Emerg Drugs 2016 Jun;21(2):133-452016-06-01 00:00:002016-06-01 00:00:00Emerging immunotherapies for glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-24 / Nat Rev Urol 2016 Jun;13(6):334-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-24 / Nat Rev Urol 2016 Jun;13(6):334-522016-05-24 00:00:002016-05-24 00:00:00Oncolytic virotherapy for urological cancers
